| Literature DB >> 27880843 |
Sandra Janezic1,2, Mojca Potocnik1, Valerija Zidaric1, Maja Rupnik1,2.
Abstract
Clostridium difficile is one of the most important human and animal pathogens. However, the bacterium is ubiquitous and can be isolated from various sources. Here we report the prevalence and characterization of C. difficile in less studied environmental samples, puddle water (n = 104) and soil (n = 79). C. difficile was detected in 14.4% of puddle water and in 36.7% of soil samples. Environmental strains displayed antimicrobial resistance patterns comparable to already published data of human and animal isolates. A total of 480 isolates were grouped into 34 different PCR ribotypes. More than half of these (52.9%; 18 of 34) were already described in humans or animals. However, 14 PCR ribotypes were new in our PCR ribotype library and all but one were non-toxigenic. The multilocus sequence analysis of these new PCR ribotypes revealed that non-toxigenic environmental isolates are phylogenetically distinct and belong to three highly divergent clades, two of which have not been described before. Our data suggest that environment is a potential reservoir of genetically diverse population of C. difficile.Entities:
Mesh:
Year: 2016 PMID: 27880843 PMCID: PMC5120845 DOI: 10.1371/journal.pone.0167101
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Overview of C. difficile genotypes isolated from soil and puddles with number of isolates obtained and number of sampling sites where the genotype was found.
| PCR ribotype | Toxinotype | Puddle water | Soil | PCR ribotype found in | |
|---|---|---|---|---|---|
| humans | animals | ||||
| 002 | 0 | 7/1 | + | + | |
| 005 | 0 | 10/1 | + | + | |
| 010 | Tox-, lok 1/3+ | 12/1 | 80/6 | + | + |
| 012 | 0 | 1/1 | + | + | |
| 014/020 | 0 | 26/3 | 81/7 | + | + |
| 015 | Tox-, lok 1/3+ | 11/1 | + | + | |
| 023 | IV (CDT+) | 2/1 | 8/1 | + | + |
| 029 | 0 | 9/1 | + | + | |
| 103 | 0 | 20/2 | + | + | |
| 153(CE) | XId (CDT+) | 5/1 | - | - | |
| 244 | IXb (CDT+) | 1/1 | + | + | |
| 251 | IIIb (CDT+) | 9/1 | 5/1 | + | + |
| SLO 002 | Tox-, lok 1/3+ | 10/1 | + | + | |
| SLO 029 | 0 | 5/1 | + | + | |
| SLO 069 | 0 | 12/2 | + | + | |
| SLO 092 | Tox-, lok 1/3+ | 2/1 | - | - | |
| SLO 187 | XId (CDT+) | 9/1 | + | - | |
| SLO 191 | 0 | 5/1 | + | - | |
| SLO 192 | Tox-, lok 1/3+ | 7/3 | + | - | |
| SLO 204 | Tox-, lok 1/3- | 2/1 | 16/5 | - | - |
| SLO 205 | Tox-, lok 1/3- | 19/3 | - | - | |
| SLO 206 | Tox-, lok 1/3- | 9/1 | - | - | |
| SLO 208 | Tox-, lok 1/3- | 1/1 | - | - | |
| SLO 214 | Tox-, lok 1/3- | 11/1 | - | - | |
| SLO 215 | Tox-, lok 1/3- | 4/1 | - | - | |
| SLO 216 | Tox-, lok 1/3- | 8/1 | - | - | |
| SLO 218 | Tox-, lok 1/3- | 13/1 | - | - | |
| SLO 221 | Tox-, lok 1/3- | 1/1 | - | - | |
| SLO 222 | Tox-, lok 1/3- | 10/1 | - | - | |
| SLO 223 | Tox-, lok 1/3- | 12/2 | - | - | |
| SLO 229 | Tox-, lok 1/3- | 12/2 | + | - | |
| SLO 230 | XXXII | 15/1 | - | - | |
| SLO 240 | Tox-, lok 1/3- | 9/1 | - | - | |
| SLO 251 | Tox-, lok 1/3- | 1/1 | - | - | |
| Total nr. of isolates/total nr. of | 119/15 | 361/29 | na | na | |
| Nr. of PCR ribotypes | 15 | 24 | na | na | |
| Nr. of tested samples | 104 | 79 | na | na | |
1Tox—refers to PaLoc negative strains; lok1/3+ refers to strains where 115-bp sequence, replacing the PaLoc was PCR amplified; lok1/3—refers to PaLoc negative strains where 115-bp sequence could not be amplified with primers lok1/lok3; CDT+ indicates presence of binary toxin genes
2number of isolates/number of sampling sites; na—not applicable
Antibiotic resistance and/or reduced susceptibilities of environmental C. difficile isolated against 15 antimicrobial agents.
| Antibiotic | Clinical breakpoint (mg/L) | ECOFF (mg/L) | Isolates with reduced susceptibility (n = 35) | Resistant isolates (n = 35) | PCR ribotypes |
|---|---|---|---|---|---|
| Imipenem | ≥16 | nd | na | 13 (37.1%) | 005, 023, 244, 251, SLO 029, SLO 069, SLO 191, SLO 192, SLO 204, SLO 205, SLO 214, SLO 218 |
| Erythromycin | ≥8 | >2 | 12 (34.3%) | 3 (8.6%) | 005, 014/020, 015, 103, 244, 251, SLO 002, SLO 191, SLO 192, SLO 214, SLO 218, SLO 222 |
| Daptomycin | nd | >4 | 5 (14.3%) | na | 005, 244, 251, SLO 218, SLO 229 |
| Clindamycin | ≥8 | >16 | 3 (8.6%) | 10 (28.6%) | 103, SLO 002, SLO 222 |
| Tetracycline | ≥16 | >0.25 | 3 (8.6%) | 0.0 | SLO 002, SLO 192, SLO 240 |
| Rifampicin | ≥4 | >0.004 | 3 (8.6%) | 0.0 | SLO 229, SLO 240 |
| Tigecycline | ND | >0.25 | 0.0 | na | na |
| Moxifloxacin | ≥8 | >4 | 0.0 | 0.0 | na |
| Metronidazole | ≥32 | >2 | 0.0 | 0.0 | na |
| Vancomycin | ≥16 | >2 | 0.0 | 0.0 | na |
| Fusidic acid | nd | >2 | 0.0 | na | na |
| Amoxicillin | ≥16 | nd | 0.0 | 0.0 | na |
| Linezolid | ≥8 | nd | 0.0 | 0.0 | na |
| Ceftriaxone | ≥64 | nd | 0.0 | 0.0 | na |
| Levofloxacin | ≥8 | nd | 0.0 | 0.0 | na |
abased on Clinical and Laboratory Standards Institute (CLSI)
bECOFF—Epidemiological cut-off values according to EUCAST; na—not applicable
Multilocus sequence types and allelic profiles of environmental isolates.
| PCR ribotype | Isolate | ST | Clade | MLST allelic profile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SLO 204 | ZZV14-6150 | 341 | C-III | 26 | 35 | 39 | 52 | 31 | 49 | 52 |
| SLO 204 | ZZV13-5731 | 344 | C-III | 26 | 36 | 39 | 52 | 31 | 49 | 52 |
| SLO 204 | ZZV14-6044 | 344 | C-III | 26 | 36 | 39 | 52 | 31 | 49 | 52 |
| SLO 205 | ZZV14-6045 | 343 | C-III | 26 | 36 | 37 | 54 | 31 | 49 | 52 |
| SLO 206 | ZZV14-5902 | 339 | C-III | 26 | 35 | 37 | 54 | 31 | 49 | 52 |
| SLO 208 | ZZV15-6048 | 343 | C-III | 26 | 36 | 37 | 54 | 31 | 49 | 52 |
| SLO 214 | ZZV15-6009 | 343 | C-III | 26 | 36 | 37 | 54 | 31 | 49 | 52 |
| SLO 218 | ZZV15-6154 | 342 | C-III | 26 | 35 | 39 | 54 | 31 | 47 | 50 |
| SLO 221 | ZZV14-6345 | 337 | C-II | 25 | 21 | 38 | 53 | 21 | 36 | 53 |
| SLO 222 | ZZV15-6383 | 338 | C-II | 25 | 21 | 38 | 53 | 21 | 48 | 53 |
| SLO 223 | ZZV15-6388 | 345 | C-III | 27 | 37 | 39 | 55 | 31 | 49 | 54 |
| SLO 229 | ZZV14-6387 | 335 | C-I | 13 | 17 | 22 | 33 | 18 | 31 | 51 |
| SLO 230 | ZZV15-6597 | 346 | C-III | 27 | 38 | 40 | 56 | 31 | 49 | 55 |
| SLO 240 | ZZV15-6598 | 347 | C-III | 28 | 39 | 41 | 57 | 30 | 50 | 56 |
| SLO 251 | ZZV14-6153 | 336 | C-III | 24 | 36 | 37 | 54 | 31 | 49 | 50 |
Fig 1Phylogenetic relationship of C. difficile based on MLST sequences.
The Maximum likelihood phylogenetic tree was constructed based on the alignment of concatenated DNA sequences of the seven housekeeping genes. Clades 1–5 and C-I were already described and clades C-II and C-III are new. In clade C-II a strain with ST200 (toxinotype XXXII) is present and is described in our recent publication [36].